Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study, expected to commence in 2024 Carlsbad, CA, Jan. 29, 2024 — […]
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
Carlsbad, CA, Jan. 09, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held January 25-27, 2024 in Las Vegas, NV. […]
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
– Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation – Lead program, PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) advancing toward completion of IND-enabling studies with IND filing expected by Q3 2024 Carlsbad, CA, Dec. 28, 2023 — Palisade […]
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anticipated to commence Phase 1 clinical study in 2024 – Strong financial position with cash to execute on strategy and achieve significant milestones into 2025 Carlsbad, […]
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 — Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio […]
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 11, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32. Ladenburg Thalmann […]
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven […]
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 07, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering. […]
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel disease (IBD) represents a multi-billion dollar market opportunity with current therapies achieving a clinical remission rate of less than 20% on average Carlsbad, CA, Sept. 06, 2023 […]
Palisade Bio Reports Second Quarter 2023 Financial Results
– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund operations through 2024 Carlsbad, CA, Aug. 11, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today summarized […]